Deborah Jean Lee Wong

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.7K citations · Full text

Medicine, Oncology, Pharmacology +11

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial

Michael R. Migden, Nikhil I. Khushalani, Anne Lynn S. Chang et al. · The Lancet Oncology · 2020 · 480 citations · Full text

Medicine, Dermatology, Oncology +13

First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study

Ryan J. Sullivan, Jeffrey R. Infante, Filip Jankú et al. · Cancer Discovery · 2017 · 418 citations

Medicine, Oncology, Pharmacology +14

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Antoni Ribas, Theresa Medina, Shivaani Kummar et al. · Cancer Discovery · 2018 · 341 citations · Full text

Medicine, Immunology, Oncology +17

Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study

Allen M. Chen, Carol Felix, Pin‐Chieh Wang et al. · The Lancet Oncology · 2017 · 331 citations · Full text

Medicine, Oncology, Radiation Oncology +9